Fortfahren mit
Größe auswählen
| Größe/SKU | Verfügbarkeit | Preis |
|---|---|---|
200 mg | Warenkorb auf Verfügbarkeit prüfen | € 1.190,00 |
Über diesen Artikel
grade
pharmaceutical primary standard
agency
USP
API family
rufinamide
manufacturer/tradename
USP
application(s)
pharmaceutical
pharmaceutical (small molecule)
format
neat
SMILES string
NC(=O)c1cn(Cc2c(F)cccc2F)nn1
InChI
1S/C10H8F2N4O/c11-7-2-1-3-8(12)6(7)4-16-5-9(10(13)17)14-15-16/h1-3,5H,4H2,(H2,13,17)
InChI key
POGQSBRIGCQNEG-UHFFFAOYSA-N
Gene Information
General description
For further information and support please go to the website of the issuing Pharmacopoeia.
Application
- Rufinamide Tablets
Biochem/physiol Actions
Analysis Note
Other Notes
1 of 1
Dieser Artikel | |||
|---|---|---|---|
| description United States Pharmacopeia (USP) Reference Standard | description ≥98% (HPLC), powder | description pharmaceutical analytical impurity (PAI) | description European Pharmacopoeia (EP) Reference Standard |
| manufacturer/tradename USP | manufacturer/tradename - | manufacturer/tradename USP | manufacturer/tradename EDQM |
| grade pharmaceutical primary standard | grade - | grade pharmaceutical analytical impurity (PAI) | grade pharmaceutical primary standard |
| application(s) pharmaceutical (small molecule) | application(s) - | application(s) pharmaceutical small molecule | application(s) - |
| format neat | format - | format neat | format - |
| agency USP | agency - | agency USP | agency BP |
| API family rufinamide | API family - | API family - | API family tetracaine |
Still not finding the right product?
Explore all of our products under Rufinamid
Signalwort
Warning
Gefahrencodes
Sicherheitshinweise
Hazard Classifications
Carc. 2 - Repr. 2 - STOT SE 3
Zielorgane
Central nervous system
Lagerklasse
11 - Combustible Solids
Was ist los?
WGK 3
Flammpunkt (°F)
Not applicable
Flammpunkt (°C)
Not applicable
Hier finden Sie alle aktuellen Versionen:
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.




